Purpose: Tranexamic acid (TXA) is playing an increasing role in haemorrhage management. Its use is associated with a reduction in all-cause mortality and a reduction in death due to bleeding1. The role of TXA in maxillofacial trauma is unclear, with few publications considering its role in haemorrhage control following maxillofacial trauma. Methodology: A systematic review of the literature was performed, with articles discussing maxillofacial trauma and the role of TXA included. Results: Two studies2,3 considered the role of tranexamic acid in maxillofacial trauma presentations. Both identified a significant reduction in blood loss in patients that received intravenous TXA immediately pre-operatively and neither TXA cohort required blood transfusion intra-operatively or in the post-operative period. Neither study identified an adverse event associated with TXA administration. Conclusion: TXA is associated with a reduction in blood loss in maxillofacial trauma, as well as reduced transfusion requirements. 1. Roberts I, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess.2013;17(10):1-79. doi:10.3310/hta17100 2. Dakir A, et al. Efficacy of Tranexamic Acid in Reducing Blood Loss during Maxillofacial Trauma Surgery-A Pilot Study. J Clin Diagn Res.2014;8(5):ZC06-ZC8. doi:10.7860/JCDR/2014/8680.4313 3. Khiabani K, et al. Is Preoperative Administration of Tranexamic Acid Effective on Blood Loss Reduction in Mandibular Fracture Surgeries? A Triple-Blind Randomized Clinical Trial. J Oral Maxillofac Surg.2021;79(2):429.e1-429.e7.doi:10.1016/j.joms.2020.09.011